Biomarin raises Voxzogo sales expectations again
US-based Biomarin has recently launched its dwarfism drug Voxzogo, and the company is now increasing its sales expectations for the drug for the second time.
by christian bundgaard, translated by daniel pedersen
When Biomarin released its full-year report for 2021, the company also increased its sales expectations for Voxzogo, a treatment for achondroplasia, also known as dwarfism.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biomarin projects 2022 Voxzogo sales of USD 115m
For subscribers
Ascendis Pharma initiates clinical trial of dwarfism drug
For subscribers
Biomarin's dwarfism drug receives FDA approval
For subscribers
